Related Experiment Videos
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy
Norio Ieiri1, Osamu Hotta, Yoshio Taguma
1Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan. no-ieiri@pf6.so-net.ne.jp
Insights
Lipoprotein glomerulopathy (LPG) is a kidney disease that can lead to kidney failure. Intensive lipid-lowering therapy successfully treated a patient with LPG, reversing kidney damage and proteinuria.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Lipoprotein glomerulopathy (LPG) is a rare kidney disease characterized by lipoprotein thrombi in glomeruli, leading to progressive renal dysfunction and end-stage renal failure.
- Currently, no established treatment exists for LPG, posing a significant challenge in managing affected patients.
Observation:
- A 36-year-old woman with LPG and nephrotic syndrome was treated with a combination of fenofibrate, niceritrol, ethyl-icosapentate, and probucol.
- The patient exhibited a significant reduction in urinary protein excretion and improved hyperlipidemia following the intensive lipid-lowering therapy.
Findings:
- Proteinuria completely resolved 11 months after initiating treatment.
- A repeat renal biopsy confirmed the complete disappearance of lipoprotein thrombi, indicating regression of the disease.
- The treatment regimen effectively controlled abnormal lipoproteinemia, a presumed key factor in LPG pathogenesis.
Implications:
- These findings suggest that aggressive lipid-lowering therapy may induce regression of lipoprotein glomerulopathy.
- Controlling abnormal lipoproteinemia is crucial for managing LPG and potentially reversing kidney damage.
- This case highlights a promising therapeutic strategy for LPG, warranting further investigation in larger studies.
Abstract:
Lipoprotein glomerulopathy (LPG), characterized by glomerular lipoprotein thrombi, presumably composed of abnormal apolipoprotein E (apoE), leads to a progressive decline in renal function and eventually results in end-stage renal failure. A successful treatment for LPG has not yet been established. The authors treated a 36-year-old woman with LPG and exhibiting a nephrotic syndrome using an intensive lipid-lowering therapy consisting of fenofibrate (300 mg), niceritrol (750 mg), ethyl-icosapentate (1,800 mg), and probucol (500 mg). After the start of treatment, a remarkable decrease in urinary protein excretion and improvement in the hyperlipidemia were obtained; proteinuria was no longer detected 11 months after the initiation of treatment. A second biopsy performed 11 months after the initiation of treatment showed the complete disappearance of the lipoprotein thrombi that had been observed in a diffuse and global manner in the first renal biopsy. These findings suggest that typical LPG could be regressed if the abnormal lipoproteinemia is controlled sufficiently.